Cardiol Therapeutics (CRDL) Return on Capital Employed (2021 - 2026)

Cardiol Therapeutics' Return on Capital Employed history runs 5 years deep, the most recent figure standing at 175.85% for Q1 2026.

• Quarterly Return on Capital Employed rose 1878.0% year-over-year to 175.85% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 175.85% (up 1878.0% YoY) and the FY2025 annual result came in at 155.56%, down 1043.0% from the prior year.
• Return on Capital Employed was 175.85% for Q1 2026 at Cardiol Therapeutics, up from 194.64% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 53.99% in Q1 2022 and bottomed at 194.64% in Q1 2025.
• A 4-year average of 116.93% and a median of 76.03% in 2022 frame the typical range for Return on Capital Employed.
• Annual changes were most pronounced in 2022 — Return on Capital Employed soared 3482 bps — and 2025, when it slumped 1554 bps.
• Cardiol Therapeutics' Return on Capital Employed stood at 76.03% in 2022, then sank by 136 bps to 179.09% in 2024, then decreased by 9 bps to 194.64% in 2025, then climbed by 10 bps to 175.85% in 2026.
• Business Quant data shows CRDL's Return on Capital Employed at 175.85% in Q1 2026, 194.64% in Q1 2025, and 179.09% in Q1 2024.